Evidence map›Paper›PMID 35139659›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2022

Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor.

Bastien Poitier, Richard Chocron, Christophe Peronino, Aurélien Philippe, Yuri Pya, Nadia Rivet, Ulysse Richez, Mahabbat Bekbossynova, Nicolas Gendron, Marc Grimmé and 13 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. The total artificial heart: where have we been, where are we now, where are we going?Indian journal of thoracic and cardiovascular surgery · 2023
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 5 countries.

Bastien PoitierUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Richard ChocronUniversité de Paris, PARCC, INSERM, F-75015 Paris, France, Emergency department, AP-HP, Georges Pompidou European Hospital, France (R.C.).ORCID 0000-0002-5498-8937
Christophe PeroninoUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
Aurélien PhilippeUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
Yuri PyaNational Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.).
Nadia RivetUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
Ulysse RichezCarmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).
Mahabbat BekbossynovaNational Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.).ORCID 0000-0003-2834-617X
Nicolas GendronUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).ORCID 0000-0003-4852-4738
Marc GrimméCarmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).ORCID 0000-0001-5525-4858
Marie Cécile BoriesUniversité de Paris, Cardiac Surgery Department, AP-HP, Georges Pompidou European Hospital, France (M.C.B.).
Julie BrichetUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
Antoine CapelUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Jeanne RancicUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
Benoit VedieAP-HP, Biochemistry Department, Georges Pompidou European Hospital, France (B.V.).ORCID 0000-0003-1167-5356
Jean Christian RousselCardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, France (J.C.R.).ORCID 0000-0003-3928-6977
Anne-Sophie JannotDepartment of Bioinformatics, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France (A.-S.J.).
Piet Jansen
Alain CarpentierCarmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).
Peter IvakDepartment of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.).
Christian LatremouilleUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Ivan NetukaDepartment of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.).
David M SmadjaUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).ORCID 0000-0001-7731-9202
Inserm · FRAssistance Publique – Hôpitaux de Paris · FREiffage (France) · FRInstitute of Clinical and Experimental Medicine · CZNational Center for Biotechnology · KZHôpital Européen · FRHôpital Saint-Jacques · FRJanssen (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation.

methodsWe examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume.

resultsThe cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output (

conclusionsWe demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.

Indexed as

Heart, Artificialvon Willebrand DiseasesAdultHemoglobinsHemolysisHumansvon Willebrand FactorHemoglobinsvon Willebrand Factorblood volumeheart failureheart transplantationhemodynamicsplasma

Identifiers

PMID35139659
OpenAlexW4211090960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.